AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

Core Viewpoint - AtaiBeckley Inc has appointed Michael Faerm as Chief Financial Officer, effective March 9, 2026, to lead the company's financial strategy and operations as it advances its clinical-stage programs, particularly BPL-003 moving toward Phase 3 [1][4]. Group 1: Executive Appointment - Michael Faerm brings over 25 years of experience in life sciences, equity research, and investment banking to his new role as CFO [2]. - Anne Johnson, the current CFO since 2024, will transition to Chief Accounting Officer, ensuring continuity in financial operations [3]. Group 2: Company Strategy and Pipeline - AtaiBeckley focuses on developing rapid-acting, durable mental health treatments, with a pipeline that includes BPL-003 for treatment-resistant depression, VLS-01 for treatment-resistant depression, and EMP-01 for social anxiety disorder [5]. - BPL-003 is currently in Phase 3 planning, while VLS-01 and EMP-01 are in Phase 2 clinical development [5].